share_log

4D Molecular Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(7.88%),Deep Track Biotechnology Master Fund, Ltd.(7.88%), etc.

4D Molecular Therapeutics | SC 13G/A:超過5%持股股東披露文件(修正)-Deep Track Capital, LP(7.88%),Deep Track Biotechnology Master Fund, Ltd.(7.88%)等

美股SEC公告 ·  2024/11/14 22:17
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息